Fig. 6: Confirmation that the hypoxic sEV signature prognosticates disease progression in NSCLC patients. | Communications Biology

Fig. 6: Confirmation that the hypoxic sEV signature prognosticates disease progression in NSCLC patients.

From: An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer

Fig. 6

a 18F-FDG PET/CT images of two patients (patient 44 and 53 of the confirmation cohort) that are tracked in B and C at indicated points (yellow arrowhead; site of progression). b In support of the discovery cohort, there was no significant difference in sEV concentration in patients that progress within 18 months compared to patients that progress after 18 months. Patient 44 and 53 are indicated by arrowheads. c The four signature proteins are significantly elevated in sEVs derived from patients that progress within 18 months compared to patients without progress at 18 months. d Kaplan–Meier plot of DFS of NSCLC patients using the logistic model from the discovery cohort indicates a clear separation in DFS. *p < 0.05, **p < 0.01.

Back to article page